VIKING-MALT-GROUP
30.8.2021 14:43:06 CEST | Business Wire | Press release
Marcin Siemion has decided to leave the Viking Malt Group. He has over many years successfully developed the Viking Malt Polish business and been a key contributor to creating a strong commercial position for Viking Malt Group in the international malting industry. We thank him for his contribution to the company and wish him all the best both privately and professionally. Following this, we would like to announce the following changes in Viking Malt Sales organization:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210830005352/en/
Malin Andersson has been appointed VP Sales in Viking Malt Group
Malin Andersson will be responsible for the sales strategy and the volume customers. She will become a member of the Group Management Team and in her role help Viking Malt in its mission of providing value-adding malted products to our customers for their success. Malin has been with the company since 1997, successfully leading sales, marketing, customer service and logistics in Viking Malt Sweden as well as had the role of a Site Manager and as latest also the role of Managing Director of Viking Malt Sweden. She has in depth knowledge of the company and the industry with a wide international network in malting and brewing industry. She holds an Executive MBA from Copenhagen Business School.
Annika Wilhelmson will lead the Craft and Partner Sales
At the same time, we have the pleasure to announce that Annika Wilhelmson will be responsible for the Craft and Partner Sales and Marketing. She will continue her work in the Group Management Team and cover Innovation, Quality and CSR in the Vice President role. Annika started with Viking Malt Group in 2017 as VP New Business Development. She holds a doctor´s degree in chemical engineering from Helsinki University of Technology and is specialized in malting. Prior to Viking Malt she has worked at VTT in several roles including senior scientist, project manager and Key Account Manager responsible for sales.
Tomasz Malec appointed Viking Malt Poland Managing Director
VP Supply Chain Tomasz Malec will take over the role of the MD of the Viking Malt Polish entity. He continues in his role as the VP Supply Chain and as the member of the Management Team for the Group.
Before Viking Malt Tomasz Malec worked for Carlsberg for almost twenty years, latest as the VP Production for Carlsberg Poland. Prior to Carlsberg he has worked for Elkometech, Danfoss and Computerland SA as well as Huta Auluminimum Konin SA in different roles. Tomasz holds a degree in engineering from Łódź Technical University, Poland.
“I am delighted to offer these important roles to three of our key leaders. I feel confident that we will continue to serve our customers around the world with high quality malt - and secure that the company with over 130 years of history will stay strong for many years to come“, says CEO Kasper Madsen.
Viking Malt Group has production in 5 countries: Finland, Sweden, Denmark and Lithuania as well as two plants in Poland. The production capacity is 600 000 t/a and the turnover of the group is appr. 250 million euros and the company employ appr. 260 employees. Viking Malt is the largest malting company in Scandinavia, 5th largest in Europe and 9th in the world. It is the leading company in specialty malts in the global market. Viking Malt Group is owned by Polttimo (62,5 %) and Svenska Lantmännen (37,5 %).
View source version on businesswire.com: https://www.businesswire.com/news/home/20210830005352/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 14:48:00 CEST | Press release
Rapid growth shows strong demand for a new trading model where users can make market predictions without risking their own capital Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
